|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||
| Net loss | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation for property, plant and equipment | ||||
| Amortization of intangible assets | ||||
| Reduction in the carrying amount of the right-of-use assets | ||||
| (Gain) loss on disposal of long-lived assets | ||||
| Write-down of inventories | ||||
| Impairment of intangible assets | ||||
| Share-based compensation expense | ||||
| Change in fair value of investments | ||||
| Share of net loss of an equity investee | ||||
| Precision Autoimmune Therapeutics Co., Ltd | ||||
| Total share of net loss of an equity investee | ||||
| Impairment loss of long-term investments | ||||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | ||||
| Receivable from a related party | ||||
| Inventories | ||||
| Prepaid expenses and other | ||||
| Accounts payable | ||||
| Accrued liabilities and other liabilities | ||||
| Income tax payable | ||||
| Net cash used in operating activities | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||
| Proceeds from disposal of property and equipment | ||||
| Purchases of property, plant and equipment | ||||
| Proceeds from sale of intangible assets | ||||
| Purchase of intangible assets | ||||
| Proceeds from sales of equity securities | ||||
| Cash paid to acquire equity interests in an equity method investee | ||||
| Precision Autoimmune Therapeutics Co., Ltd | ||||
| Total cash paid to acquire equity interests in an equity method investee | ||||
| Purchase of short term investments and term deposits | ||||
| Proceeds from sales or maturity of short term investments and term deposits | ||||
| Proceeds from extinguishment of investment in a convertible loan | ||||
| Net cash provided by (used in) investing activities | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||
| Proceeds from issuance of ordinary shares | ||||
| Payment of issuance costs | ||||
| Proceeds from issuance of convertible note | ||||
| Proceeds from exercise of share options | ||||
| Dividend payment to Wuxi LP | ||||
| Proceeds from bank borrowings | ||||
| Repurchase of ordinary shares | ||||
| Net cash provided by (used in) financing activities | ||||
| Effect of exchange rate change on cash and cash equivalents | ||||
| Net decrease in cash and cash equivalents | ||||
| Cash and cash equivalents at beginning of year | ||||
| Cash and cash equivalents at end of year | ||||
| Supplemental disclosure of cash flow information: | ||||
| Interest paid | ||||
| Income taxes paid | ||||
| Non-cash investing and financing activities: | ||||
| Payables related to property, plant and equipment | ||||
| Exchange of redeemable noncontrolling interest to long term borrowing (Note 11) | ||||
Loading...
